Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XENT

Intersect ENT (XENT) Stock Price, News & Analysis

Intersect ENT logo

About Intersect ENT Stock (NASDAQ:XENT)

Advanced Chart

Key Stats

Today's Range
$28.24
$28.24
50-Day Range
$28.24
$28.24
52-Week Range
$15.92
$28.25
Volume
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Stock News Headlines

Kiatnakin Bank PCL (KKP)
XENT Historical Data
The #1 AI Energy Stock
Nearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths.
See More Headlines

XENT Stock Analysis - Frequently Asked Questions

Intersect ENT, Inc. (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The medical equipment provider had revenue of $24.40 million for the quarter, compared to analysts' expectations of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG) and Air Transport Services Group (ATSG).

Company Calendar

Last Earnings
11/02/2021
Today
6/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:XENT
Employees
433
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$159.63 million
Net Margins
-161.94%
Pretax Margin
-163.16%

Debt

Sales & Book Value

Annual Sales
$106.75 million
Price / Cash Flow
N/A
Book Value
($2.06) per share
Price / Book
-13.71

Miscellaneous

Free Float
33,104,000
Market Cap
$954.91 million
Optionable
Optionable
Beta
1.45

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:XENT) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners